CRP and chronic obstructive pulmonary disease: COPD patients expressing the highest baseline CRP or TNF-alpha levels also did not demonstrate a significant impact of infliximab on changes from baseline in clinical and biomarker measurements, unlike results recently reported for sarcoidosis [21].